Loading...
Keywords
Last Name
Institution
 Back to Details

Connection

Andrea Gaedigk to Polymorphism, Genetic

This is a "connection" page, showing publications Andrea Gaedigk has written about Polymorphism, Genetic.

 
Connection Strength
  
 
 
4.532
  
  1. Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021 09; 110(3):662-676.
    View in: PubMed
    Score: 0.749
  2. Turner AJ, Aggarwal P, Boone EC, Haidar CE, Relling MV, Derezinski AD, Broeckel U, Gaedigk A. Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. J Mol Diagn. 2021 05; 23(5):577-588.
    View in: PubMed
    Score: 0.729
  3. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry. 2013 Oct; 25(5):534-53.
    View in: PubMed
    Score: 0.437
  4. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 2008 Feb; 83(2):234-42.
    View in: PubMed
    Score: 0.290
  5. Langlois AWR, Chenoweth MJ, Twesigomwe D, Scantamburlo G, Whirl-Carrillo M, Sangkuhl K, Klein TE, Nofziger C, Tyndale RF, Gaedigk A. PharmVar GeneFocus: CYP2A6. Clin Pharmacol Ther. 2024 Oct; 116(4):948-962.
    View in: PubMed
    Score: 0.231
  6. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol. 2001 Oct; 79(10):841-7.
    View in: PubMed
    Score: 0.190
  7. Nofziger C, Turner AJ, Sangkuhl K, Whirl-Carrillo M, Ag?ndez JAG, Black JL, Dunnenberger HM, Ruano G, Kennedy MA, Phillips MS, Hachad H, Klein TE, Gaedigk A. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020 01; 107(1):154-170.
    View in: PubMed
    Score: 0.168
  8. Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CMT, van den Anker JN. Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study. Clin Pharmacokinet. 2018 10; 57(10):1325-1336.
    View in: PubMed
    Score: 0.154
  9. Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics. 1998 Aug; 8(4):305-13.
    View in: PubMed
    Score: 0.153
  10. S?nchez-Mart?n A, S?nchez-Iglesias S, Garc?a-Berrocal B, Lorenzo C, Gaedigk A, Isidoro-Garc?a M. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Pharmacogenomics. 2016 08; 17(12):1291-3.
    View in: PubMed
    Score: 0.133
  11. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017 01; 19(1):69-76.
    View in: PubMed
    Score: 0.132
  12. Hicks JK, Bishop JR, Sangkuhl K, M?ller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 08; 98(2):127-34.
    View in: PubMed
    Score: 0.123
  13. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: a critical assessment and call for standardization. Curr Drug Metab. 2014 Feb; 15(2):218-32.
    View in: PubMed
    Score: 0.112
  14. Sutter ME, Gaedigk A, Albertson TE, Southard J, Owen KP, Mills LD, Diercks DB. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure. Clin Toxicol (Phila). 2013 Aug; 51(7):540-4.
    View in: PubMed
    Score: 0.108
  15. Abduljalil K, Frank D, Gaedigk A, Klaassen T, Tomalik-Scharte D, Jetter A, Jaehde U, Kirchheiner J, Fuhr U. Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clin Pharmacol Ther. 2010 Nov; 88(5):643-51.
    View in: PubMed
    Score: 0.089
  16. Wright GE, Niehaus DJ, Dr?gem?ller BI, Koen L, Gaedigk A, Warnich L. Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet. 2010 Jul; 74(4):340-50.
    View in: PubMed
    Score: 0.087
  17. Gaedigk A, Isidoro-Garc?a M, Pearce RE, S?nchez S, Garc?a-Solaesa V, Lorenzo-Romo C, Gonzalez-Tejera G, Corey S. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur J Clin Pharmacol. 2010 Sep; 66(9):859-64.
    View in: PubMed
    Score: 0.086
  18. Gaedigk A, Ryder DL, Bradford LD, Leeder JS. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem. 2003 Jun; 49(6 Pt 1):1008-11.
    View in: PubMed
    Score: 0.053
  19. Gaedigk A, Bradford LD, Marcucci KA, Leeder JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002 Jul; 72(1):76-89.
    View in: PubMed
    Score: 0.050
  20. Carranza-Leon D, Dickson AL, Gaedigk A, Stein CM, Chung CP. CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice. Pharmacogenomics J. 2021 08; 21(4):484-490.
    View in: PubMed
    Score: 0.046
  21. Hongkaew Y, Gaedigk A, Wilffert B, Ngamsamut N, Kittitharaphan W, Limsila P, Sukasem C. Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Sci Rep. 2021 02 18; 11(1):4158.
    View in: PubMed
    Score: 0.046
  22. McInnes G, Dalton R, Sangkuhl K, Whirl-Carrillo M, Lee SB, Tsao PS, Gaedigk A, Altman RB, Woodahl EL. Transfer learning enables prediction of CYP2D6 haplotype function. PLoS Comput Biol. 2020 11; 16(11):e1008399.
    View in: PubMed
    Score: 0.045
  23. Gaedigk A. Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther. 2000 Feb; 38(2):61-8.
    View in: PubMed
    Score: 0.042
  24. Dalton R, Lee SB, Claw KG, Prasad B, Phillips BR, Shen DD, Wong LH, Fade M, McDonald MG, Dunham MJ, Fowler DM, Rettie AE, Schuetz E, Thornton TA, Nickerson DA, Gaedigk A, Thummel KE, Woodahl EL. Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity. Clin Transl Sci. 2020 01; 13(1):147-156.
    View in: PubMed
    Score: 0.042
  25. Wagner JB, Abdel-Rahman S, Van Haandel L, Gaedigk A, Gaedigk R, Raghuveer G, Kauffman R, Leeder JS. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics. J Clin Pharmacol. 2018 06; 58(6):823-833.
    View in: PubMed
    Score: 0.037
  26. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, M?rike K, St?ven T, Eichelbaum M. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics. 1998 Feb; 8(1):15-26.
    View in: PubMed
    Score: 0.037
  27. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, Gaedigk A, Agundez J, Sadhasivam S, Klein TE, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017 08; 102(2):213-218.
    View in: PubMed
    Score: 0.035
  28. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, M?ller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 07; 102(1):37-44.
    View in: PubMed
    Score: 0.034
  29. Crews KR, Gaedigk A, Dunnenberger HM, Leeder JS, Klein TE, Caudle KE, Haidar CE, Shen DD, Callaghan JT, Sadhasivam S, Prows CA, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther. 2014 04; 95(4):376-82.
    View in: PubMed
    Score: 0.028
  30. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, M?ller DJ, Gaedigk A, Stingl JC. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013 05; 93(5):402-8.
    View in: PubMed
    Score: 0.026
  31. Crews KR, Gaedigk A, Dunnenberger HM, Klein TE, Shen DD, Callaghan JT, Kharasch ED, Skaar TC. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther. 2012 Feb; 91(2):321-6.
    View in: PubMed
    Score: 0.024
  32. Bradford LD, Gaedigk A, Leeder JS. High frequency of CYP2D6 poor and "intermediate" metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull. 1998; 34(4):797-804.
    View in: PubMed
    Score: 0.009
  33. Grant DM, Hughes NC, Janezic SA, Goodfellow GH, Chen HJ, Gaedigk A, Yu VL, Grewal R. Human acetyltransferase polymorphisms. Mutat Res. 1997 May 12; 376(1-2):61-70.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.